EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

Improved Detection of Bone Metastases in Children and Young Adults with Ferumoxytol-enhanced MRI

Ali Rashidi iD, Lucia Baratto iD, Ashok Joseph Theruvath iD, Elton Benjamin Greene, Praveen Jayapal, K Elizabeth Hawk, Rong Lu, Jayne Seekins, Sheri L Spunt iD, Allison Pribnow iD, Heike E Daldrup-Link iD

Radiology: Imaging Cancer · 2023

DOI: 10.1148/rycan.220080 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Radiology: Imaging Cancer, 2023. Verfasst von Ali Rashidi und 10 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Radiology, Molecular Imaging Program at Stanford (A.R., L.B., A.J.T., K.E.H., J.S., H.E.D.L.), and Department of Radiology, Di…. Hauptthemen laut MEDLINE: Bone Marrow Neoplasms, Bone Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAMS NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate if ferumoxytol can improve the detection of bone marrow metastases at diffusion-weighted (DW) MRI in pediatric and young adult patients with cancer. Materials and Methods In this secondary analysis of a prospective institutional review board-approved study (ClinicalTrials.gov identifier NCT01542879), 26 children and young adults (age range: 2-25 years; 18 males) underwent unenhanced or ferumoxytol-enhanced whole-body DW MRI between 2015 and 2020. Two reviewers determined the presence of bone marrow metastases using a Likert scale. One additional reviewer measured signal-to-noise ratios (SNRs) and tumor-to-bone marrow contrast. Fluorine 18 (18F) fluorodeoxyglucose (FDG) PET and follow-up chest CT, abdominal and pelvic CT, and standard (non-ferumoxytol enhanced) MRI served as the reference standard. Results of different experimental groups were compared using generalized estimation equations, Wilcoxon rank sum test, and Wilcoxon signed rank test.

Results

The SNR of normal bone marrow was significantly lower at ferumoxytol-enhanced MRI compared with unenhanced MRI at baseline (21.380 ± 19.878 vs 102.621 ± 94.346, respectively; P = .03) and after chemotherapy (20.026 ± 7.664 vs 54.110 ± 48.022, respectively; P = .006). This led to an increased tumor-to-marrow contrast on ferumoxytol-enhanced MRI scans compared with unenhanced MRI scans at baseline (1397.474 ± 938.576 vs 665.364 ± 440.576, respectively; P = .07) and after chemotherapy (1099.205 ± 864.604 vs 500.758 ± 439.975, respectively; P = .007). Accordingly, the sensitivity and diagnostic accuracy for detecting bone marrow metastases were 96% (94 of 98) and 99% (293 of 297), respectively, with the use of ferumoxytol-enhanced MRI compared with 83% (106 of 127) and 95% (369 of 390) with the use of unenhanced MRI.

Conclusion

Use of ferumoxytol helped improve the detection of bone marrow metastases in children and young adults with cancer. Keywords: Pediatrics, Molecular Imaging-Cancer, Molecular Imaging-Nanoparticles, MR-Diffusion Weighted Imaging, MR Imaging, Skeletal-Appendicular, Skeletal-Axial, Bone Marrow, Comparative Studies, Cancer Imaging, Ferumoxytol, USPIO © RSNA, 2023 ClinicalTrials.gov registration no. NCT01542879 See also the commentary by Holter-Chakrabarty and Glover in this issue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Marrow NeoplasmsBone NeoplasmsAdolescentAdultChildChild, PreschoolHumansMaleYoung AdultFerrosoferric OxideMagnetic Resonance ImagingProspective Studies

Stichwörter der Autor:innen

Bone MarrowCancer ImagingComparative StudiesFerumoxytolMR ImagingMR–Diffusion Weighted ImagingMolecular Imaging–CancerMolecular Imaging–NanoparticlesPediatricsSkeletal-AppendicularSkeletal-AxialUSPIO

Substanzen

Ferrosoferric Oxide

Autor:innen und Institutionen

  • From the Department of Radiology, Molecular Imaging Program at Stanford (A.R., L.B., A.J.T., K.E.H., J.S., H.E.D.L.), and Department of Radiology, Division of Pediatric Radiology (E.B.G., P.J.), Lucile Packard Children'…

ORCID-Profile: Ali Rashidi, Lucia Baratto, Ashok Joseph Theruvath, Sheri L Spunt, Allison Pribnow, Heike E Daldrup-Link

Förderung

  • NCI NIH HHS
  • NIAMS NIH HHS
  • NICHD NIH HHS
  • NCATS NIH HHS
  • National Cancer Institute
  • Stanford Cancer Institute
  • Stanford Center for Clinical and Translational Research and Education

Zitieren

APA

Rashidi, A., Baratto, L., Theruvath, A. J., Greene, E. B., Jayapal, P., Hawk, K. E., Lu, R., Seekins, J., Spunt, S. L., Pribnow, A., & Daldrup-Link, H. E. (2023). Improved Detection of Bone Metastases in Children and Young Adults with Ferumoxytol-enhanced MRI. Radiology: Imaging Cancer. https://doi.org/10.1148/rycan.220080

Vancouver

Rashidi A, Baratto L, Theruvath AJ, Greene EB, Jayapal P, Hawk KE, et al. Improved Detection of Bone Metastases in Children and Young Adults with Ferumoxytol-enhanced MRI. Radiology: Imaging Cancer. 2023. doi:10.1148/rycan.220080

BibTeX
@article{Rashidi2023,
  author = {Rashidi, Ali and Baratto, Lucia and Theruvath, Ashok Joseph and Greene, Elton Benjamin and Jayapal, Praveen and Hawk, K Elizabeth and Lu, Rong and Seekins, Jayne and Spunt, Sheri L and Pribnow, Allison and Daldrup-Link, Heike E},
  title = {Improved Detection of Bone Metastases in Children and Young Adults with Ferumoxytol-enhanced MRI},
  journal = {Radiology: Imaging Cancer},
  year = {2023},
  doi = {10.1148/rycan.220080}
}
Kostenlos starten →